Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 7/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | FPR2 | P25090 | 1/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.52 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | IGF1R | P08069 | 1/20 | 0.49 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.49 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2877898 | 0.89 | EPHX2 (0.68) | P2RY1EPHX2CA12CA1CA2 | |
| SCHEMBL2872551 | 0.88 | EPHX2 (0.62) | P2RY1EPHX2CA12CA1CA2 | |
| SCHEMBL2877802 | 0.87 | P2RY1 (0.54) | P2RY1EPHX2STING1 | |
| SCHEMBL2878651 | 0.87 | MAPT (0.58) | P2RY1EPHX2CA12CA1CA2 | |
| SCHEMBL2875876 | 0.85 | EPHX2 (0.62) | P2RY1EPHX2CA12CA1CA2 | |
| SCHEMBL2877416 | 0.85 | P2RY1 (0.53) | P2RY1EPHX2STING1 | |
| SCHEMBL2872757 | 0.85 | P2RY1 (0.54) | P2RY1EPHX2CA12CA1CA2 | |
| SCHEMBL3163849 | 0.84 | PPIA (0.64) | P2RY1EPHX2FPR2IGF1RSTING1 | |
| SCHEMBL2872773 | 0.83 | IDO1 (0.56) | P2RY1EPHX2CA12CA1CA2 | |
| SCHEMBL2872767 | 0.83 | EPHX2 (0.59) | P2RY1EPHX2CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1899299-B1 | C-LINKED CYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2010-10-20 | — | — | EP | claimed |
| EP-1899299-B1 | C-LINKED CYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2010-10-20 | — | — | EP | disclosed |
| US-7700620-B2 | C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700620-B2 | C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-20 | — | — | US | disclosed |
| US-20060293336-A1 | C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293336-A1 | C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | P2RY11, P2RY1, P2RY13 | P2RY1 2/4885EPHX2 1294/4885NOX1 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.